Theravance Biopharma (TBPH) Non-Current Debt (2018 - 2022)
Theravance Biopharma (TBPH) posted quarterly Non-Current Debt of $396.1 million for Q2 2022, up 5.61% year-over-year from $375.1 million in Q2 2021, and up 3.11% quarter-over-quarter from $384.2 million in Q1 2022.
Theravance Biopharma (TBPH) Non-Current Debt (2018 - 2022) Analysis & Trends
Theravance Biopharma (TBPH) has reported Non-Current Debt for 5 consecutive years, with $396.1 million the latest figure, recorded in Q2 2022.
- In Q2 2022, Non-Current Debt rose 5.61% year-over-year to $396.1 million; the TTM figure through Jun 2022 stood at $396.1 million (up 5.61% YoY), while the FY2021 annual figure was $371.4 million, changed 0.41% from the prior year.
- Non-Current Debt advanced to $396.1 million in Q2 2022 per TBPH's latest filing, from $384.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $396.1 million in Q2 2022 and bottomed at $217.7 million in Q2 2019.
- Historically, Non-Current Debt has averaged $326.3 million across 5 years, with a median of $373.9 million in 2020.
- Annual changes were most pronounced in 2019 — Non-Current Debt retreated 4.46% — and 2020, when it soared 73.18%.
- Theravance Biopharma's Non-Current Debt stood at $229.5 million in 2018, then declined by 4.46% to $219.3 million in 2019, then surged by 70.03% to $372.9 million in 2020, then slipped by 0.41% to $371.4 million in 2021, then increased by 6.67% to $396.1 million in 2022.
- Business Quant data shows TBPH's Non-Current Debt at $396.1 million in Q2 2022, $384.2 million in Q1 2022, and $371.4 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 396.13 Mn |
| Mar 31, 2022 | 384.16 Mn |
| Dec 31, 2021 | 371.36 Mn |
| Sep 30, 2021 | 375.57 Mn |
| Jun 30, 2021 | 375.07 Mn |
| Mar 31, 2021 | 375.18 Mn |
| Dec 31, 2020 | 372.87 Mn |
| Sep 30, 2020 | 384.48 Mn |
| Jun 30, 2020 | 375.27 Mn |
| Mar 31, 2020 | 373.85 Mn |
| Dec 31, 2019 | 219.30 Mn |
| Sep 30, 2019 | 222.01 Mn |
| Jun 30, 2019 | 217.72 Mn |
| Mar 31, 2019 | 221.40 Mn |
| Dec 31, 2018 | 229.54 Mn |